Brief: Rallybio Announces Preliminary Multiple Dose Data From The Completed Phase 1 Safety And Pharmacokinetics Study For RLYB212
28/11/2023 12:35
Nov 28 (Reuters) - Rallybio Corp RLYB.O :
* RALLYBIO ANNOUNCES PRELIMINARY MULTIPLE DOSE DATA FROM THE
COMPLETED PHASE 1 SAFETY AND PHARMACOKINETICS STUDY FOR RLYB212,
AN ANTI-HPA-1A MONOCLONAL ANTIBODY FOR THE PREVENTION OF FETAL
AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
* RALLYBIO CORP - RLYB212 PHASE 2 STUDY EXPECTED TO COMMENCE
IN 2H
2024
* RALLYBIO CORP - PRELIMINARY DATA SUPPORT RLYB212 ONCE
MONTHLY
SUBCUTANEOUS DOSING IN PHASE 2 STUDY
Source text for Eikon: ID:nBw4hvBMKa
Further company coverage: RLYB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx